Absorption: Well absorbed following oral administration.
Distribution: Well distributed to extravascular tissues. Binds extensively to red blood cells.
Half-Life: 63 hr (plasma).
ROUTE | ONSET | PEAK | DURATION |
---|---|---|---|
PO | unknown | 26 hr (capsule); 0.55 hr (oral suspension) | 24 hr |
‡Requires 2 wk of dosing to achieve steady-state plasma concentrations.
Contraindicated in:
Use Cautiously in:
Derm: DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS), oligohydrosis (↑ in children), rash, STEVENS-JOHNSON SYNDROME, TOXIC EPIDERMAL NECROLYSIS
EENT: amblyopia, angle closure glaucoma, ↑intraocular pressure, myopia, pharyngitis, tinnitus
F and E: metabolic acidosis
GI: anorexia, nausea, vomiting
GU: kidney stones
Neuro: drowsiness, fatigue, abnormal gait, agitation/irritability, depression, dizziness, encephalopathy, hyperesthesia, incoordination, psychomotor slowing, psychosis, SUICIDAL THOUGHTS, tremor, weakness
Resp: cough
Drug-drug:
Lab Test Considerations: